title: Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis.
abstract: Platelet-activating factor is an endogenous phospholipid produced by a wide variety of inflammatory cells. Platelet-activating factor induces severe pathological changes in various organs and, among numerous potent effects, causes bowel necrosis. Pouchitis is a poorly understood complication of ileoanal pouch anastomosis which occurs in patients who undergo surgery for ulcerative colitis. The aim of this study was to measure ileal or fecal platelet-activating factor and lyso platelet-activating factor contents in normal volunteers (n = 12), in patients with terminal ileostomy (n = 7), and in patients with ileoanal anastomosis (n = 15) (8 patients have pouchitis defined by the presence of ulcerations on the reservoir). Fecal samples were processed and assessed for platelet-activating factor by platelet aggregation assay. The aggregating material was further characterized as platelet-activating factor by the following: inhibition of the platelet aggregation it induced by specific platelet-activating factor receptor antagonist (BN 52021; IHB, Le Plessis Robinson, France); abolition of platelet aggregation after incubation with phospholipase A2 but not with lipase A1; and retention time on high-performance liquid chromatography. Stool platelet-activating factor content (in nanograms per gram of stool, mean +/- 1SD) was significantly increased in patients with pouchitis (22.2 +/- 16 ng/g) compared with patients with normal reservoir (1.59 +/- 0.63 ng/g, P less than 0.01), terminal ileostomy (0.59 +/- 0.43 ng/g, P less than 0.01), and healthy controls (0 +/- 0 ng/g of stool, P less than 0.001). Lyso platelet-activating factor (nanograms per gram of stool) was increased in patients with pouchitis (10,704 +/- 5499 ng/g) compared with patients with normal reservoir (4721 +/- 4549 ng/g of stool, P less than 0.05), terminal ileostomy (3042 +/- 4019 ng/g, P less than 0.02), and healthy volunteers (128 +/- 107 ng/g, P less than 0.001). In patients with ileoanal anastomosis and pouchitis, increased platelet-activating factor production could be implicated in the inflammation and ulcerations observed in the reservoir.
authors.affiliation: Service d'Hepato-gastroentérologie, Hôpital Cochin, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Chaussade
authors.forename: Y
authors.initials: Y
authors.lastname: Denizot
authors.forename: P
authors.initials: P
authors.lastname: Valleur
authors.forename: J
authors.initials: J
authors.lastname: Nicoli
authors.forename: P
authors.initials: P
authors.lastname: Raibaud
authors.forename: J
authors.initials: J
authors.lastname: Guerre
authors.forename: P
authors.initials: P
authors.lastname: Hautefeuille
authors.forename: D
authors.initials: D
authors.lastname: Couturier
authors.forename: J
authors.initials: J
authors.lastname: Benveniste
mesh_terms: D000328:Adult; D001003:Anal Canal / Q000601:surgery; D000714:Anastomosis, Surgical; D003093:Colitis, Ulcerative / Q000601:surgery*; D005243:Feces / Q000737:chemistry*; D005260:Female; D006801:Humans; D007081:Ileostomy; D007082:Ileum / Q000601:surgery; D008297:Male; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000032:analysis*; D010974:Platelet Aggregation / Q000502:physiology; D011183:Postoperative Complications / Q000378:metabolism*
chemical_list: C029271:O-deacetyl platelet activating factor; D010972:Platelet Activating Factor